z-logo
open-access-imgOpen Access
Anti – Androgenic Activity of Caesalpinia bonducella in Androgen-induced Polycystic Ovarian Syndrome Rats
Author(s) -
M. Sumithra,
V. Chitra,
Murali Krishna Moka,
. Padaleeswaran,
Safeeq Ahamed
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i55a33826
Subject(s) - testosterone propionate , testosterone (patch) , caesalpinia , medicine , endocrinology , androgen , anabolism , hormone , body weight , biology , traditional medicine
Aim:  Our goal was to use the androgen and anabolic steroid (AAS) Testosterone Propionate (TP) to create a novel animal model to study polycystic ovaries. Materials and Methods: Thirty albino female Wistar rats weighing 200 – 250 g were split into five groups with six rats in each group. Group I was treated as standard control, Group II was treated as the PCOS induced group, Group III was treated as a standard group, Clomiphene citrate (20 mg per kg body weight), intraperitoneally (I.P) along with a 4 mg TP injection intramuscularly (I.M) in an oily solution, Group IV was treatment control group treated with a hydro-alcoholic extract of Caesalpinia bonducella (CBHAE) at a dose of 200 mg per kg body weight. Group V was given CBHAE at 400 mg per kg of body weight. Blood collected from animals examined for hormonal parameters and ovaries is subjected to histopathological studies.  Results: There was a fall in testosterone volume and an increase in the efflux of female hormone constituents, which improved the ovarian development and helped to regulate menses. Conclusion: Significantly lower levels of Testosterone were produced as a result of the extract, which also showed superior anti-androgenic properties. However, additional intervention is recommended in order to investigate the therapeutic effect of Caesalpinia bonducella seed in further detail.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here